Clonal hematopoiesis and its emerging effects on cellular therapies.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
27
03
2021
accepted:
23
06
2021
revised:
22
06
2021
pubmed:
4
7
2021
medline:
18
11
2021
entrez:
3
7
2021
Statut:
ppublish
Résumé
The accumulation of somatic mutations in hematopoietic stem cells during aging, leading to clonal expansion, is linked to a higher risk of cardiovascular mortality and hematologic malignancies. Clinically, clonal hematopoiesis is associated with a pro-inflammatory phenotype of hematopoietic cells and their progeny, inflammatory conditions and a poor outcome for patients with hematologic neoplasms and solid tumors. Here, we review the relevance and complications of clonal hematopoiesis for the treatment of hematologic malignancies with cell therapeutic approaches. In autologous and allogeneic hematopoietic stem cell transplantation native hematopoietic and immune effector cells of clonal origin are transferred, which may affect outcome of the procedure. In chimeric antigen receptor modified T-cell therapy, the effectiveness may be altered by preexisting somatic mutations in genetically modified effector cells or by unmodified bystander cells harboring clonal hematopoiesis. Registry studies and carefully designed prospective trials will be required to assess the relative roles of donor- and recipient-derived individual clonal events for autologous and allogeneic cell therapies and to incorporate novel insights into therapeutic strategies.
Identifiants
pubmed: 34215849
doi: 10.1038/s41375-021-01337-8
pii: 10.1038/s41375-021-01337-8
pmc: PMC8249428
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2752-2758Informations de copyright
© 2021. The Author(s).
Références
Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori Y, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777–89.
pubmed: 30110635
doi: 10.1016/j.celrep.2018.07.037
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348:880–6.
pubmed: 25999502
pmcid: 4471149
doi: 10.1126/science.aaa6806
Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362:911–7.
pubmed: 30337457
pmcid: 6298579
doi: 10.1126/science.aau3879
Blokzijl F, De Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature. 2016;538:260–4.
pubmed: 27698416
pmcid: 5536223
doi: 10.1038/nature19768
Yizhak K, Aguet F, Kim J, Hess JM, Kübler K, Grimsby J, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. 2019;364:eaaw0726.
pubmed: 31171663
pmcid: 7350423
doi: 10.1126/science.aaw0726
Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477–87.
pubmed: 25426838
pmcid: 4290021
doi: 10.1056/NEJMoa1409405
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
pubmed: 25426837
pmcid: 4306669
doi: 10.1056/NEJMoa1408617
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–8.
pubmed: 25326804
pmcid: 4313872
doi: 10.1038/nm.3733
Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130:742–52.
pubmed: 28483762
pmcid: 5553576
doi: 10.1182/blood-2017-02-769869
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.
pubmed: 12042769
doi: 10.1038/nrg816
Cypris O, Božić T, Wagner W. Chicken or egg: is clonal hematopoiesis primarily caused by genetic or epigenetic aberrations? Front Genet. 2019;10:785.
pubmed: 31552094
pmcid: 6746886
doi: 10.3389/fgene.2019.00785
Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015;47:1402–7.
pubmed: 26551669
pmcid: 4783858
doi: 10.1038/ng.3441
Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642–50.
pubmed: 22561516
pmcid: 3366033
doi: 10.1038/ng.2271
Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651–8.
pubmed: 22561519
pmcid: 3372921
doi: 10.1038/ng.2270
Gao T, Ptashkin R, Bolton KL, Sirenko M, Fong C, Spitzer B, et al. Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nat Commun. 2021;12:338.
pubmed: 33436578
pmcid: 7804935
doi: 10.1038/s41467-020-20565-7
Terao C, Suzuki A, Momozawa Y, Akiyama M, Ishigaki K, Yamamoto K, et al. Chromosomal alterations among age-related haematopoietic clones in Japan. Nature. 2020;584:130–5.
pubmed: 32581364
pmcid: 7489641
doi: 10.1038/s41586-020-2426-2
Zekavat SM, Lin SH, Bick AG, Liu A, Paruchuri K, Uddin MM, et al. Hematopoietic mosaic chromosomal alterations and risk for infection among 767,891 individuals without blood cancer. medRxiv. 2020. https://doi.org/10.1101/2020.11.12.20230821 .
Wang L, Swierczek SI, Drummond J, Hickman K, Kim S, Walker K, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia. 2014;28:935–8.
pubmed: 24413320
pmcid: 4532385
doi: 10.1038/leu.2014.7
Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586:763–8.
pubmed: 33057201
pmcid: 7944936
doi: 10.1038/s41586-020-2819-2
Lin SH, Wang Y, Hartley SW, Karyadi DM, Lee OW, Zhu B, et al. In utero exposure to zidovudine-containing antiretroviral therapy and clonal hematopoiesis in HIV-exposed uninfected newborns. AIDS. 2021. https://doi.org/10.1097/QAD.0000000000002894 .
Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.
pubmed: 27546487
pmcid: 4996934
doi: 10.1038/ncomms12484
Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400–4.
pubmed: 29988082
pmcid: 6485381
doi: 10.1038/s41586-018-0317-6
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16.
pubmed: 25931582
pmcid: 4624443
doi: 10.1182/blood-2015-03-631747
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289–301.
pubmed: 19474426
doi: 10.1056/NEJMoa0810069
Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908–19.
pubmed: 29491455
doi: 10.1038/s41375-018-0047-7
Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079–95.
pubmed: 28823558
pmcid: 5755977
doi: 10.1016/j.cell.2017.07.032
Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013;210:2641–59.
pubmed: 24218140
pmcid: 3832937
doi: 10.1084/jem.20131141
Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia. 2012;26:2216–23.
pubmed: 22469782
doi: 10.1038/leu.2012.94
Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011;108:14566–71.
pubmed: 21873190
pmcid: 3167529
doi: 10.1073/pnas.1112317108
Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20:11–24.
pubmed: 21723200
pmcid: 3194039
doi: 10.1016/j.ccr.2011.06.001
Koya J, Kataoka K, Sato T, Bando M, Kato Y, Tsuruta-Kishino T, et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat Commun. 2016;7:10924.
pubmed: 27010239
pmcid: 4820786
doi: 10.1038/ncomms10924
Challen GA, Sun D, Mayle A, Jeong M, Luo M, Rodriguez B, et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 2014;15:350–64.
pubmed: 25130491
pmcid: 4163922
doi: 10.1016/j.stem.2014.06.018
Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2012;44:23–31.
doi: 10.1038/ng.1009
Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52:378–87.
pubmed: 32203468
pmcid: 7216752
doi: 10.1038/s41588-020-0595-4
Ostrander EL, Kramer AC, Mallaney C, Celik H, Koh WK, Fairchild J, et al. Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic progenitor cell fitness. Stem Cell Rep. 2020;14:551–60.
doi: 10.1016/j.stemcr.2020.02.011
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
pubmed: 24522528
pmcid: 4991939
doi: 10.1038/nature13038
Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548–53.
pubmed: 24550281
pmcid: 3932921
doi: 10.1073/pnas.1324297111
Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, et al. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest. 2017;127:3657–74.
pubmed: 28872462
pmcid: 5617681
doi: 10.1172/JCI93041
Jeong M, Park HJ, Celik H, Ostrander EL, Reyes JM, Guzman A, et al. Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep. 2018;23:1–10.
pubmed: 29617651
pmcid: 5908249
doi: 10.1016/j.celrep.2018.03.025
Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584–96.
pubmed: 20541703
pmcid: 2909585
doi: 10.1016/j.ccr.2010.05.015
Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012;120:166–72.
pubmed: 22627765
pmcid: 3390954
doi: 10.1182/blood-2012-01-402396
Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23:700–13.
pubmed: 30388424
pmcid: 6224657
doi: 10.1016/j.stem.2018.10.004
Eskelund CW, Husby S, Favero F, Klausen TW, Rodriguez-Gonzalez FG, Kolstad A, et al. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood. 2020;135:2000–4.
pubmed: 32181815
doi: 10.1182/blood.2019003539
Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018;23:833–49.
pubmed: 30526882
pmcid: 6317370
doi: 10.1016/j.stem.2018.10.013
Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dubé MP, et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018;132:277–80.
pubmed: 29764839
doi: 10.1182/blood-2018-01-829937
Dai YJ, Wang YY, Huang JY, Xia L, Shi XD, Xu J, et al. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. Proc Natl Acad Sci USA. 2017;114:5237–42.
pubmed: 28461508
pmcid: 5441829
doi: 10.1073/pnas.1703476114
Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera. Blood. 2006;108:3128–34.
pubmed: 16757685
doi: 10.1182/blood-2006-04-017392
Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood. 2016;127:893–7.
pubmed: 26631115
pmcid: 4760092
doi: 10.1182/blood-2015-10-677021
Cai Z, Lu X, Zhang C, Nelanuthala S, Aguilera F, Hadley A, et al. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid. J Clin Invest. 2021;131:e140707.
pmcid: 7773407
doi: 10.1172/JCI140707
Lewis NE, Petrova-Drus K, Huet S, Epstein-Peterson ZD, Gao Q, Sigler AE, et al. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Adv. 2020;4:2261–71.
pubmed: 32442302
pmcid: 7252546
doi: 10.1182/bloodadvances.2020001636
Tiacci E, Venanzi A, Ascani S, Marra A, Cardinali V, Martino G, et al. High-risk clonal hematopoiesis as the origin of AITL and NPM1 -mutated AML. N Engl J Med. 2018;379:981–4.
pubmed: 30184450
doi: 10.1056/NEJMc1806413
Mouly E, Ghamlouch H, Della-Valle V, Scourzic L, Quivoron C, Roos-Weil D, et al. B-cell tumor development in Tet2-deficient mice. Blood Adv. 2018;2:703–14.
pubmed: 29581109
pmcid: 5873234
doi: 10.1182/bloodadvances.2017014118
Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20:25–38.
pubmed: 21723201
doi: 10.1016/j.ccr.2011.06.003
Klimkowska M, Nannya Y, Gran CE, Mansson R, Douagi I, Ogawa S, et al. Absence of a common founder mutation in patients with co-occurring myelodysplastic syndrome and plasma cell disorder. Blood. 2020;137:1260–3.
doi: 10.1182/blood.2020007555
Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019;4:25–33.
pubmed: 30566180
doi: 10.1001/jamacardio.2018.3965
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.
pubmed: 28636844
pmcid: 6717509
doi: 10.1056/NEJMoa1701719
Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383:2628–38.
pubmed: 33108101
pmcid: 7847551
doi: 10.1056/NEJMoa2026834
Miller PG, Sperling AS, Gibson CJ, Viswanathan K, Castellano C, McConkey M, et al. Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood. 2020;136:3051–5.
pubmed: 32961550
doi: 10.1182/blood.2020008206
pmcid: 7770567
Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. medRxiv. 2020. https://doi.org/10.1101/2020.11.25.20233163 .
Arends CM, Weiss M, Christen F, Eulenberg-Gustavus C, Rousselle A, Kettritz R, et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica. 2020;105:e264–7.
pubmed: 31582546
pmcid: 7271609
doi: 10.3324/haematol.2019.223305
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219–26.
pubmed: 33106634
pmcid: 7891089
doi: 10.1038/s41588-020-00710-0
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21:374–82.
pubmed: 28803919
pmcid: 5591073
doi: 10.1016/j.stem.2017.07.010
Miller PG, Gibson CJ, Mehta A, Sperling AS, Frederick DT, Manos MP, et al. Fitness landscape of clonal hematopoiesis under selective pressure of immune checkpoint blockade. JCO Precis Oncol. 2020;4:1027–33.
doi: 10.1200/PO.20.00186
Amini RM, Ljungström V, Abdulla M, Cavelier L, Pandzic T, Hollander P, et al. Clonal hematopoiesis in patients with high-grade B-cell lymphoma is associated with inferior outcome. Am J Hematol. 2020;95:e287–9.
doi: 10.1002/ajh.25927
Cook EK, Luo M, Rauh MJ. Clonal hematopoiesis and inflammation: partners in leukemogenesis and comorbidity. Exp Hematol. 2020;83:85–94.
pubmed: 32001341
doi: 10.1016/j.exphem.2020.01.011
Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020;136:1606–14.
pubmed: 32736379
pmcid: 8209629
Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–7.
pubmed: 28104796
pmcid: 5542057
doi: 10.1126/science.aag1381
Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol. 2017;55:56–70.
pubmed: 28826859
doi: 10.1016/j.exphem.2017.08.001
Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389–93.
pubmed: 26287468
pmcid: 4697747
doi: 10.1038/nature15252
Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ Res. 2020;128:216–28.
pubmed: 33155517
doi: 10.1161/CIRCRESAHA.120.317104
Leoni C, Montagner S, Rinaldi A, Bertoni F, Polletti S, Balestrieri C, et al. Dnmt3a restrains mast cell inflammatory responses. Proc Natl Acad Sci USA. 2017;114:E1490–9.
pubmed: 28167789
pmcid: 5338402
doi: 10.1073/pnas.1616420114
Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10:eaan8292.
pubmed: 29643232
pmcid: 6442466
doi: 10.1126/scitranslmed.aan8292
Kramer AC, Kothari A, Wilson WC, Celik H, Nikitas J, Mallaney C, et al. Dnmt3a regulates T-cell development and suppresses T-ALL transformation. Leukemia. 2017;31:2479–90.
pubmed: 28321121
pmcid: 5636646
doi: 10.1038/leu.2017.89
Carty SA, Gohil M, Banks LB, Cotton RM, Johnson ME, Stelekati E, et al. The loss of TET2 promotes CD8 + T cell memory differentiation. J Immunol. 2018;200:82–91.
pubmed: 29150566
doi: 10.4049/jimmunol.1700559
Spegarova JS, Lawless D, Mohamad SMB, Engelhardt KR, Doody G, Shrimpton J, et al. Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. Blood. 2020;136:1055–66.
doi: 10.1182/blood.2020005844
Berger G, Kroeze LI, Koorenhof-Scheele TN, De Graaf AO, Yoshida K, Ueno H, et al. Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. Blood. 2018;131:1846–57.
pubmed: 29311096
doi: 10.1182/blood-2017-09-805879
Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, et al. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018;9:455.
pubmed: 29386642
pmcid: 5792556
doi: 10.1038/s41467-018-02858-0
Husby S, Favero F, Nielsen C, Sørensen BS, Bæch J, Grell K, et al. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020;34:3256–68.
pubmed: 32203146
doi: 10.1038/s41375-020-0795-z
Chitre S, Stölzel F, Cuthill K, Streetly M, Graham C, Dill C, et al. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. Leukemia. 2018;32:2020–4.
pubmed: 30026569
doi: 10.1038/s41375-018-0208-8
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017;35:1598–605.
pubmed: 28068180
pmcid: 5455707
doi: 10.1200/JCO.2016.71.6712
Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.
pubmed: 32533060
pmcid: 7293239
doi: 10.1038/s41467-020-16805-5
Gifford G, Hesson L, Wong JWH, Carroll A, Gabrielli S, Bai L, et al. Poor mobilization of autologous CD34+ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. Br J Haematol. 2021:193:841–4.
Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020;4:885–92.
pubmed: 32150606
pmcid: 7065480
doi: 10.1182/bloodadvances.2019001157
Ortmann CA, Dorsheimer L, Abou-El-Ardat K, Hoffrichter J, Assmus B, Bonig H, et al. Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation. Cell Rep. 2019;27:2022–8.
pubmed: 31091442
doi: 10.1016/j.celrep.2019.04.064
Engel N, Rovo A, Badoglio M, Labopin M, Basak GW, Beguin Y, et al. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. Leukemia. 2019;33:508–17.
pubmed: 30050122
doi: 10.1038/s41375-018-0218-6
Herold S, Kuhn M, von Bonin M, Stange T, Platzbecker U, Radke J, et al. Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia. 2017;31:1637–40.
pubmed: 28348390
doi: 10.1038/leu.2017.104
Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134:924–34.
pubmed: 31292117
doi: 10.1182/blood.2019001212
Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25:1408–14.
pubmed: 31477906
doi: 10.1038/s41591-019-0549-5
Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375–85.
pubmed: 30403573
doi: 10.1200/JCO.2018.79.2184
Gibson CJ, Kennedy JA, Nikiforow S, Kuo FC, Alyea EP, Ho V, et al. Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017;130:91–4.
pubmed: 28446434
pmcid: 5501150
doi: 10.1182/blood-2017-01-764951
Gibson CJ, Kim HT, Murdock HM, Hambley B, Zhao L, Green L, et al. DNMT3A clonal hematopoiesis in older donors is associated with improved survival in recipients after allogeneic hematopoietic cell transplant. Blood. 2020;136:26.
doi: 10.1182/blood-2020-142925
Giavridis T, Van Der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat Med. 2018;24:731–8.
pubmed: 29808005
pmcid: 6410714
doi: 10.1038/s41591-018-0041-7
Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48.
pubmed: 29808007
doi: 10.1038/s41591-018-0036-4
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87.
pubmed: 32780846
pmcid: 7422135
doi: 10.1182/bloodadvances.2020002509
Yue X, Lio CWJ, Samaniego-Castruita D, Li X, Rao A. Loss of TET2 and TET3 in regulatory T cells unleashes effector function. Nat Commun. 2019;10:2011.
pubmed: 31043609
pmcid: 6494907
doi: 10.1038/s41467-019-09541-y
Yue X, Trifari S, Äijö T, Tsagaratou A, Pastor WA, Zepeda-Martínez JA, et al. Control of Foxp3 stability through modulation of TET activity. J Exp Med. 2016;213:377–97.
pubmed: 26903244
pmcid: 4813667
doi: 10.1084/jem.20151438
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307–12.
pubmed: 29849141
pmcid: 6320248
doi: 10.1038/s41586-018-0178-z
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest. 2020;130:673–85.
pubmed: 31845905
doi: 10.1172/JCI130144
Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, et al. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132:1095–105.
pubmed: 29954749
pmcid: 6137556
doi: 10.1182/blood-2018-05-850339